Beam Therapeutics BEAM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's cash & equivalents?
- Beam Therapeutics (BEAM) reported cash & equivalents of $288.29M in Q1 2026.
- How has Beam Therapeutics's cash & equivalents changed year-over-year?
- Beam Therapeutics's cash & equivalents decreased by 45.4% year-over-year, from $527.91M to $288.29M.
- What is the long-term trend for Beam Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Beam Therapeutics's cash & equivalents has grown at a 12.7% compound annual growth rate (CAGR), from $162.17M to $294.94M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.